IL13RA2 and glioblastoma: On basis of an outstanding casuistic report on a patient with recurrent GBM treated with a 4-1BB-modified CAR product [30], intraventricular IL13Ra2 CAR T cell therapy is currently assessed in a phase 1 clinical trial for ependymoma, GBM, and medulloblastoma (NCT04661384), while intratumoral delivery is being tested in recurrent or refractory malignant glioma (NCT02208362).